Entry Point Capital, LLC Ironwood Pharmaceuticals Inc Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IRWD
# of Institutions
245Shares Held
170MCall Options Held
11.2MPut Options Held
28.5K-
Black Rock Inc. New York, NY22.9MShares$107 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$100 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT16.4MShares$76.4 Million18.04% of portfolio
-
State Street Corp Boston, MA9.24MShares$43.1 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA8.91MShares$41.5 Million0.15% of portfolio
About IRONWOOD PHARMACEUTICALS INC
- Ticker IRWD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 153,231,008
- Market Cap $714M
- Description
- Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...